Novo Nordisk Japan Submits J-NDA for Insuline Detemir, Long-acting Insulin Analogue.Tokyo, Japan, Dec 6, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest Japan announced on December 5 that it has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare, seeking marketing approval of Insulin Detemir Insulin detemir is a long-lasting human insulin analogue for maintaining the basal level of insulin. Novo Nordisk markets it under the trade name Levemir. It is an insulin analogue in which to the lysine amino acid at position B29 a fatty acid (myristic acid) is bound. , the company's proprietary long-acting insulin. The company has filed application for two products that use Insulin Detemir: the FlexPen pre-filled syringe syringe /sy·ringe/ (si-rinj´) (sir´inj) an instrument for injecting liquids into or withdrawing them from any vessel or cavity. and the 3ml cartridge for NovoPen. Insuline Detemir is a soluble basal insulin analogue indicated for the basic insulin therapy in both type 1 and 2 diabetes. Initially approved in Switzerland in March 2004, the agent is approved in 55 countries and currently marketed in 24 countries worldwide under the trade name of Levemir. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion